cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5683/sp3/er8ktp
title: Tracking COVID for Safer Schools

description: &lt;b&gt;Background:&lt;/b&gt; Primary and secondary schools reopened after June 2020 in Canada during the pandemic while other businesses and organizations employed work-from-home policies. The reopening was to provide better options for education and well-being, but may have put educators at risk of contracting COVID-19. &lt;br&gt;

 

&lt;b&gt;Aims of the CITF-funded study:&lt;/b&gt; The goal was to determine the prevalence of SARS-CoV-2 antibodies from infection, the psychological impact of the COVID-19 pandemic, and vaccine receptiveness among classroom educators and school staff. They also aimed to estimate asymptomatic transmission rates in schools as measured by targeted nucleic acid viral testing for SARS-CoV-2. T cell, B cell, and SARS-CoV-2 antibody assays were used to further characterize immune response to the virus. (Note: psychological impact and vaccine receptiveness data not shared with CITF Databank [1], data on asymptomatic transmission rates in children not shared with CITF Databank [2].) &lt;br&gt;

 

&lt;b&gt;Methods:&lt;/b&gt; This cohort study recruited active school staff from the Vancouver, Delta, and Richmond school districts in British Columbia. Participants provided a blood sample for serology testing and completed online questionnaires annually at the beginning of 2021, 2022 and 2023. &lt;br&gt;

 

&lt;b&gt;Contributed dataset contents: &lt;/b&gt;The datasets include 2444 participants who completed baseline questionnaires between February 2021 and June 2021. An additional 82 participants who did not complete a baseline questionnaire gave blood samples or follow-up surveys over the three sampling periods: approximately 87% of participants gave a blood sample between February 2021 and July 2021, 64% between January 2022 and March 2022, and 40% between January 2023 and May 2023. A total of 4828 samples were collected. Variables include data in the following areas of information: demographics (age, gender, race-ethnicity and indigeneity, education, household composition), general health (smokes; chronic conditions; height and weight; flu vaccine), COVID infection history (dates of positive PCR tests, hospitalizations, symptoms), adherence to COVID-19 public health guidelines, time spent with children, SARS-CoV-2 vaccination, and serology (antibodies against SARS-CoV-2 RBD, nucleocapsid, and spike proteins). &lt;br&gt;

[1]: Please contact original study team for psychological and vaccine receptiveness data.&lt;br&gt;

[2]: Please contact original study team for data on asymptomatic transmission rates in children.
description: See terms section for details.
DOI: 10.5683/sp3/pxdcsw
title: Research Platform to Screen and Protect Individuals that Work Within a Food Production, Healthcare, Research or Clinical Organization [RESPECT, study data contributed to the CITF Databank]

description: &lt;b&gt; Background: &lt;/b&gt; During lockdown, frontline workers in the food industry, healthcare and research or clinical organizations were required to work on site where they were at a risk of high exposure to SARS-CoV-2 infections from public interaction. &lt;br&gt; 
&lt;b&gt; Aims of the original study: &lt;/b&gt; The RESPECT COVID study aimed to 1) determine the asymptomatic transmission of COVID-19 in food production facilities during the pandemic; 2) monitor antibody development and immunity trends over time, and 3) evaluate participants' vaccine uptake and immune responses. &lt;br&gt;
&lt;b&gt;Methods: &lt;/b&gt; Employees from various food production facilities in the Greater Toronto Area (GTA) were enrolled in this cohort study regardless of the presence or absence of COVID-19 symptoms. Blood samples were collected at multiple timepoints to understand the longitudinal trend of antibodies induced by infection and vaccination in this population and the influence on COVID-19 transmission. &lt;br&gt; 
&lt;b&gt;Summary of the contributed data:&lt;/b&gt; The datasets include a total of 5,020 serology samples from 718 participants between January 2020 and December 2021. 508 participants (70%) have linked baseline characteristics data (completed survey). Variables include data in the following areas of information: demographic (age, gender, ethnicity and indigeneity, occupation), general health (symptoms, diseases, previous test, hospitalization), SARS-CoV-2 vaccination and serology.
description: See Data Access Portal (https://portal.citf.mcgill.ca/data-access-process)
DOI: 10.5683/sp3/v68t4b
title: Integrating Longitudinal Epidemiologic, Virologic and Immunologic Analyses to Understand COVID-19 Immunity and Infection Outcomes in Long Term Care [ILEVIA, study data contributed to the CITF Databank]

description: &lt;b&gt;Background:&lt;/b&gt; Vaccination programs are essential for protecting residents of long-term care (LTC) facilities, as they are more vulnerable to adverse outcomes from COVID-19. &lt;br&gt;

 

&lt;b&gt;Aims of the CITF-funded study:&lt;/b&gt; The main goals of the ILEVIA study were to characterize immune responses to SARS-CoV-2 infection and vaccination. The study also aimed to identify correlates of vaccine immunity, assess vaccine willingness and hesitancy, and support investigations of COVID-19 if an outbreak occurred in the presence/absence of vaccination. &lt;br&gt;

 

&lt;b&gt;Methods:&lt;/b&gt; This cohort study recruited residents and staff from LTC facilities and community members living in Vancouver, British Columbia. Participants provided a blood sample and questionnaire responses (or by proxy or chart review, as needed) at baseline, which was at or shortly before a first dose of SARS-CoV-2 vaccination for most participants. Follow-up visits occurred at 1 month after the first dose, 1 month, 3, and 6 months after second dose of the COVID-19 vaccine. Later, the study was extended to include additional follow-ups at 1 month, 3, and 6 months after the third dose of the COVID-19 vaccine. Participants provided a blood sample at every visit, and follow-up questionnaires were also administered at intervals. For immune response objectives, the team collaborated with the COVID-19 Vaccination among People Living with HIV: Immunogenicity, Effectiveness, and Safety [https://doi.org/10.5683/SP3/QVGXRL]&lt;br&gt;

 

&lt;b&gt;Contributed dataset contents:&lt;/b&gt; The data sets include 152 participants (89 healthcare workers, 24 residents from long-term care facilities and 39 seniors living in the community) who completed baseline visits between December 2020 and Apr 2021. All participants gave one or more blood samples during baseline and follow-up visits. A total of 104 participants gave blood samples in all 8 follow-up visits (5 original and 3 extended follow-ups). A total of 1,108 blood samples were collected between Dec 2020 and Aug 2022. &lt;br&gt;

A demographic and health questionnaire were completed by or for participants at baseline and follow-up visit questionnaire data is available for about 80% of the participants. Variables include data in the following areas of information: demographics (age, sex and gender, ethnicity), general health (tobacco use, chronic conditions, weight and height, flu vaccine, access to primary care), exposure risk factors (occupation, travel, gathering, compliance with COVID prevention measures), longitudinal follow-up for COVID infections (COVID test, symptoms), COVID vaccination history and willingness, and laboratory measures of immune response (serology). &lt;br&gt;
description: See Data Access Portal (https://portal.citf.mcgill.ca/data-access-process)
DOI: 10.5683/sp3/oqmlwn
title: Evaluating the safety and immunogenicity of SARS-CoV-2 vaccines among underserved urban populations with intersecting risk factors for COVID-19 morbidity and mortality: a pooled analysis of three prospective cohort studies in Vancouver, Canada [SIC19VUUP, study data contributed to the CITF Databank]

description: &lt;b&gt;Background:&lt;/b&gt; In Canada, urban centers have a high prevalence of vulnerable populations with increased risk factors for COVID-19, including homelessness, living in group settings, high-intensity substance use, and infectious diseases, who face many barriers to healthcare services. The uptake, safety, and effectiveness of COVID-19 vaccinations have not been studied in these populations yet. &lt;br&gt;

 

&lt;b&gt;Aims of the CITF funded study:&lt;/b&gt; This study aimed to 1) analyze the effectiveness of COVID-19 vaccines among different groups within vulnerable populations, 2) evaluate vaccine uptake and adherence to vaccine protocols, and 3) evaluate vaccines’ length of effectiveness against infection and any potential side effects. &lt;br&gt;

 

&lt;b&gt;Methods:&lt;/b&gt; This study enrolled participants in 3 cohorts across Vancouver, British Columbia: individuals from the Vancouver Injection Drug Users Study (VIDUS) who were 18 years or older, HIV negative, and past-30-day injection drug use, individuals from the AIDS Care Cohort (ACCESS) who were 18 years or older, HIV seropositive, and past-30-day injection/non-injection drug use, and individuals from the At-Risk Youth Study (ARYS) who were between 14 and 26 years old, “street-involved” (precariously housed or homeless), and past-30-day injection drug use. All participants were zero, partially, or fully vaccinated against COVID-19. Participants from each cohort answered a questionnaire and provided blood samples via dried blood spot and venipuncture at baseline, and at follow ups 2-months, 4- months, and 6-months post vaccination. &lt;br&gt;

 

&lt;b&gt;Contributed dataset contents:&lt;/b&gt; The datasets include 275 participants who completed baseline surveys between June 2021 and September 2021. 101 participants came from the VIDUS cohort, 97 from ACCESS, and 77 from ARYS. All participants gave one or more blood samples at baseline, and approximately 93% gave additional samples at follow ups between September 2021 and March 2022. A total of 1223 samples were collected. Variables include data in the following areas of information: demographics (age, gender, ethnicity, household composition, occupation), general health (weight and height, smoking, chronic conditions, flu vaccine), longitudinal follow-up for COVID infection (dates of positive tests, symptoms, hospitalizations), SARS-CoV-2 vaccination, and serology (IgG against SARS-CoV-2 RBD, nucleocapsid, and spike proteins).
description: See terms section for details.
DOI: 10.5683/sp3/x22qsp
title: Safety and Efficacy of Preventative COVID Vaccines [StopCoV, study data contributed to the CITF Databank]

description: &lt;b&gt;Background:&lt;/b&gt; Most COVID-19 vaccine clinical trials recruited Caucasian participants with an average age of 50 and few underlying illnesses, resulting in little information on COVID-19 vaccine efficacy in older and diverse populations. &lt;br&gt;

 

&lt;b&gt;Aims of the CITF-funded study:&lt;/b&gt; This study aimed to compare COVID-19 vaccine antibody levels between individuals aged 30-50 years old and individuals aged 70 years and older, at various time points during vaccine dosing schedules (including 24 weeks after the final dose), and to compare the safety of COVID-19 vaccines between these cohorts. &lt;br&gt;

 

&lt;b&gt;Methods:&lt;/b&gt; This cohort study recruited individuals aged 30-50 from Ontario through advertisements at vaccine distribution centers and pharmacies across Toronto and via email recruitment. Participants aged 70 years and older were recruited similarly, including email blasts through the Canadian Association of Retired Persons. Participants were followed up 7 days and 3 weeks post first dose, and 2, 12, and 24 weeks post second dose, providing a dried blood spot sample at each point. Participants also kept an eDiary for 7 days after each vaccination. &lt;br&gt;

 

&lt;b&gt;Contributed Dataset Contents:&lt;/b&gt; The datasets include 1286 participants who completed baseline surveys between May 2021 and March 2022. 87% of participants gave one or more blood samples between May 2021 and July 2022 for analysis. A total of 6993 samples were collected. Variables include data in the following areas of information: demographics (birth date, gender, ethnicity, education), general health (weight and height, smoking, chronic conditions, treatments, immunosuppressants), longitudinal follow-up for COVID infections (COVID diagnosis, symptoms, hospitalization), health events following SARS-CoV-2 vaccination, and serology (IgG against SARS-CoV-2 RBD, nucleocapsid, and spike proteins).
description: See Data Access Portal (https://portal.citf.mcgill.ca/data-access-process)
DOI: 10.5683/sp3/tlhrno
title: Saskatchewan SARS-CoV-2 Seroprevalence Study [SaskCov, study data contributed to the CITF databank]

description: &lt;b&gt;Background:&lt;/b&gt; Increased knowledge on seroprevalence rates of SARS-CoV-2 would allow for more educated public health responses in Saskatchewan and provide information for national seroprevalence estimates. &lt;br&gt;

 

&lt;b&gt;Aims of the CITF-funded study:&lt;/b&gt; This study aimed to determine the seroprevalence of SARS-CoV-2 antibodies from infection or vaccination in Saskatchewan, and to link PCR test results to seroprevalence data where possible. &lt;br&gt;

&lt;b&gt;Methods:&lt;/b&gt; This repeat cross-sectional study randomly selected residual serum samples collected for the purpose of routine screening and testing from patients across Saskatchewan. Samples were selected over three five- to nine-month periods and tested at the Saskatchewan Health Authority’s Roy Romanow Provincial Laboratory for IgG antibodies to SARS-CoV-2 trimeric spike & nucleocapsid proteins. Further microneutralization testing was conducted by the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan on a subset of the samples. Researchers obtained permission to link PCR test results collected from Saskatchewan residents to individual seroprevalence results. &lt;br&gt;

&lt;b&gt;Contributed dataset contents:&lt;/b&gt; The datasets include samples collected from more than 22,000 participants with a total of 23,956 samples collected across the three sampling periods: 10,858 between April and December 2020, 12,250 between October 2021 and June 2022, and 848 between November 2022 and March 2023. Two-thirds of participants (66%) have linked Saskatchewan Health Authority PCR data. Variables in the datasets include age, sex, region, SARS-CoV-2 serology, microneutralization (for 676 samples), and PCR testing.
description: See terms section for details.
DOI: 10.5683/sp3/5ooeut
title: Strategic Review of the Data Liberation Program – Preliminary Findings

description: DLI Consultation Report
description: DLI National Virtual Training / Formation nationale virtuelle de l'IDD
DOI: 10.5683/sp3/5pyyr6
title: Not always invisible: finding the data about marginalized and underrepresented populations in Canada

description: A sustainable data culture is also an inclusive data culture where planning, policy making, and research accounts for marginalized or underrepresented populations. Indigenous Peoples, racialized groups, and people who identify as LGBTQ+ are often underrepresented or hidden in the datasets we rely on for research and planning. Data about mental health, substance abuse, and homelessness can likewise be difficult to find, particularly for marginalized populations.
description: DLI National Virtual Training / Formation nationale virtuelle de l'IDD
DOI: 10.5683/sp3/fzmovv
title: Manitoba COVID Seroprevalence Study [MCS-Study, study data contributed to the CITF Databank]

description: &lt;b&gt;Background:&lt;/b&gt; Seroprevalence studies became an important research method for estimating the extent of SARS-CoV-2 exposure across Canada. The Cadham Provincial Laboratory (CPL) established the Manitoba COVID Seroprevalence Study to evaluate the presence of COVID-19 antibodies across the province. &lt;br&gt;

 

&lt;b&gt;Aims of the CITF-funded study:&lt;/b&gt; The study aimed to measure the seroprevalence of COVID-19 antibodies across Manitoba by age, sex, and regional health authority (RHA). It also aimed to identify the risk factors categorized by age, gender, and region to determine the proportion of the population susceptible to COVID-19 and improve case fatality ratio estimates. &lt;br&gt;

 

&lt;b&gt;Methods:&lt;/b&gt; This repeat cross-sectional study analyzed blood samples from individuals whose specimens were collected for sexually transmitted and blood-borne infections and prenatal serological testing at the CPL. From 2020 to 2023, 200 samples from each age category (1-9, 10-19, 20-39, 40-59, and 60+) were analyzed from individuals across the six RHAs in Manitoba &lt;br&gt;

 

&lt;b&gt;Contributed dataset contents:&lt;/b&gt; The dataset contains a total of 21,940 participants and all participants gave one serology sample between March 2020 and March 2023. Variables include data in the following areas of information: age, sex, regional health authority (RHA), SARS-CoV-2 serology and vaccination. Dataset includes 572 participants with missing collection date. 16,609 participants (75%) have linked COVID-19 vaccination data, and 10,584 participants (64%) gave serology data after getting vaccinated (retrospective).
description: See Data Access Portal (https://portal.citf.mcgill.ca/data-access-process)
DOI: 10.5683/sp3/pqnpsm
title: Canadian Longitudinal Study on Aging: Platform for studying the epidemiology of the COVID-19 pandemic in aging populations [CLSA, study data contributed to the CITF Databank]

description: &lt;b&gt;Background:&lt;/b&gt; As an established ongoing population-based cohort of over fifty thousand Canadians, the Canadian Longitudinal Study on Aging (CLSA) offered an opportunity to rapidly study COVID-19 immunity in Canada’s aging population. &lt;br&gt;

 

&lt;b&gt;Aims of the CITF co-funded study:&lt;/b&gt; CLSA COVID-19 study aimed to measure SARS-CoV-2 seroprevalence and seroconversion among older adults across Canada by province, age, and sex in the first two years of the pandemic (2020 and 2021). They also aimed to better understand the symptoms, risk factors, and impacts of COVID-19 through questionnaires. &lt;br&gt;

 

&lt;b&gt;Methods:&lt;/b&gt;The CLSA cohort study enrolled participants aged 45-85 across Canada via random digit dialling. Participants in the tracking cohort comprised a representative sample of Canadians, who completed cognitive tests and answered questionnaires via telephone interview at baseline and at two follow-ups. Those in the comprehensive cohort were selected from a random sample of Canadians, and participated in an at-home physical exam, answered questionnaires, completed cognitive tests, and provided blood and urine samples at baseline and two follow-ups. For participants aged 55-80 in this cohort, they completed repeated cognitive testing and brain scans for brain health surveillance. Participants in all cohorts provided a blood sample for COVID-19 antibody testing and completed a COVID-19 questionnaire. Each participant was contacted every 3 years and was followed for at least 20 years or until death.&lt;br&gt;

 

&lt;b&gt;Summary of the contributed data:&lt;/b&gt; The datasets include 19,334 participants who completed baseline surveys between October 2020 and August 2021. 23% of participants gave one or more blood samples between October 2020 and July 2021 for analysis. A total of 4,365 samples were collected. Variables include data in the following areas of information: demographics (age, gender, race-ethnicity and indigeneity, province, household composition, education), general health (smokes, chronic conditions, height and weight, flu vaccine), exposure risk factors (occupation, travel history, adherence to COVID-19 public health guidelines), COVID infection history (positive tests, symptoms, hospitalizations), SARS-CoV-2 vaccination, and qualitative serology (antibodies against SARS-CoV-2 nucleocapsid and spike proteins).
description: See Data Access Portal (https://portal.citf.mcgill.ca/data-access-process)
DOI: 10.5683/sp3/hoaksc
title: iRespite Services iRépit Datasets

description: Relevant datasets, publications, and other research artifacts related to the iRespite Services iRépit research program may be hosted here. For further details on iRespite, see: https://aimeecastro.com/irespite-services-irepit/
DOI: 10.5683/sp3/izdafx
title: Résultats d'un sondage sur la perception des Québécois à l’égard de la diversité

description: Le Centre de recherche en droit public rend public les résultats d’une étude réalisée à la demande de la Commission des droits de la personne et des droits de la jeunesse.

Le rapport de recherche présente les résultats d’un sondage portant sur la perception des Québécois à l’égard de la diversité sociale. L’étude a été dirigée par le Professeur Pierre Noreau, chercheur au CRDP et une équipe de chercheurs, de quatre universités.

Cette étude est la première d’une série de recherches destinées à évaluer périodiquement la perception de la population vis-à-vis de la diversité sociale et des droits et libertés de la personne.

Les résultats de cette étude démontrent notamment que les Québécois adhèrent majoritairement aux principes d’égalité qui fondent la Charte québécoise des droits et liberté de la personne. L’étude rend compte du respect de la majorité des Québécois à l’égard de la diversité sociale.

Les résultats complets du sondage ont été présentés par Pierre Noreau et Jacques Frémont, président de la Commission des droits des la personne et des droits de la jeunesse lors d’une conférence de presse, tenue le 14 janvier 2016 à la Maison du développement durable.

Les données de cette étude sont disponibles sur le site du Centre de recherche en droit public (CRDP) : 
https://www.crdp.umontreal.ca/nouvelles/2016/01/14/rapport-sur-la-perception-des-quebecois-a-legard-de-la-diversite/
description: Cette étude est également disponible sur le site de la Commission des droits de la personne et des droits de la jeunesse : https://www.cdpdj.qc.ca/fr/nos-positions/enjeux/sondage-droits-de-la-personne-et-diversite
DOI: 10.5683/sp3/elpygl
title: Revealing the Most Vulnerable Groups: Courtesy Stigma in Care-givers of Quebecers Autistic persons

description: Caregivers of individuals often face with "courtesy stigma," a phenomenon that adversely affects their well-being. Understanding the repercussions of this stigma is crucial not only for caregivers' mental health, but also for the quality of care provided to autistic individuals. This study aimed to explore the experience of cour-tesy stigma among caregivers of autistic individuals in Quebec, examining its prevalence and impact to identify groups that are particularly susceptible to nega-tive outcomes.
Methods
This was a cross-sectional online survey employing quota sampling and garnered responses from 194 participants. Data were collected using a computer-assisted web interview (CAWI) platform. The impact of courtesy stigma was specifically measured in terms of care burden, mental health, and overall well-being of care-givers.
Results
The findings revealed that caregivers frequently experience social exclusion, isola-tion, and work-related challenges. Notably, caregivers' health was below average compared to Quebec's general population. The vulnerable groups included female caregivers, those aged 45 or older, financially strained households, caregivers of children requiring elevated levels of support, those who self-isolated due to their autistic dependents, and those who experienced stigmatization directed at them-selves or their children in the form of rejection.
Interestingly, 60% of respondents reported that the caregiving burden was "not at all" to "somewhat" difficult, raising questions about factors that may mitigate caregiving challenges.
Conclusion
This study underscores the need for targeted public policies and interventions, par-ticularly for those at higher risk of experiencing the negative effects of courtesy stigma. By focusing on resources and support for these priority groups, we can better address the challenges faced by the families of autistic persons.